Preliminary Comparison between AQUA and Centralised ER/PgR Analysis within the TEAM Pathology Study
Bartlett, JMS Rimm, D Brookes, CL Dolled-Filhart, M Robson, T van de Velde, CH Billingham, LJ Campbell, FM Hasenburg, A Hille, ETM Kieback, D Putter, H Markopoulos, C Christiansen, J Gustavson, M Mallon, EA Meershoek-Klein, X Kranenburg, E Paridaens, Robert Seynaeve, C Rea, DW #
Cancer Research vol:69 issue:24 edition:Suppl pages:660S
San Antonio Breast Cancer Symposium location:San Antonio, USA date:9-13 December 2009
Background: The Tamoxifen and Exemestane Adjuvant Multinational (TEAM) trial identified quantitative relationships between ER/PgR (Cancer Res 69:83S) and patient prognosis, and suggested that high ER expression might be predictive for benefit from aromatase inhibitors. Conventional immunohistochemical assays, even when performed centrally, appear to be more variable than fluorescent immunohistochemical assays analysed by automated image analysis such as the AQUA system. However, output from the two systems may provide subtly different results for biomarkers. We have performed analysis of ER/PgR using AQUA technology in the TEAM pathology cohort and will present data on the full analysis of ER/PgR by central IHC and AQUA in 4600 cases. Preliminary data on ER (using a single TMA core) are included in the current analysis.
Patients & Methods: TMAs from 4598 TEAM patients were analysed by AQUA and image analysis using established algorithms performed. Comparisons between IHC and AQUA were performed and outcome data will be analysed and presented.
Results: Interim AQUA results from a single core were available from 2319 TEAM cases. Analysis of results suggested incremental increases in AQUA scores across conventional Allred categories (2-8).